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Abstract 
Review on IL1RN, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: DIRA, ICIL-1RA, IL-1RN, IL-1ra, 
IL-1ra3, IL1F3, IL1RA, IRAP, MVCD4 
HGNC (Hugo): IL1RN 
Location: 2q13 
Local order  
IL1RN is located between PSD4 gene (pleckstrin 
and Sec7 domain containing 4) and IL36RN 
(interleukin 36 receptor antagonist) and IL1F10 
(interleukin 1 family, member 10 (theta)) genes 
(NCBI). 
DNA/RNA 
Note 
IL1RN (interleukin 1 receptor antagonist) was 
identified in 1990 by Carter and cols (Carter et al., 
1990).  
It codes a protein that binds to interleukin 1 
receptor (IL1R1) and inhibits the binding of 
interleukin 1 alpha and beta (IL1A and IL1B), 
blocking the biological activity of these two 
cytokines, this is the first interleukin 1 family 
member described that has antagonist function 
(Arend, 1991; Arend and Gabay, 2000).  
 
 
IL1RN locus is 2q13. The gene length is 22901 bp (starts at 113868692 - ends at 113891592, according NCBI 08-Jul-2013). In 
this region is located along with IL36RN, IL1F10 and PSD4 and PAX8. 
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Linear diagram of IL1RN gene with their 6 exons (pink boxes). 
 
 
This gene is overexpressed in different infectious 
diseases and immune conditions. 
The IL1RN gene has a length of 22901 base-pairs, 
and is constituted by 6 exons; there are four 
isoforms described to date that are produced by 
alternative splicing: one isoform is secreted and the 
other three are cytoplasmic (Gabay et al., 1997; 
Arend and Guthridge, 2000). 
Description 
The IL1RN gene has a length of 22901 base-pairs, 
encodes a member of the interleukin 1 cytokine 
family. The gene is located on 2q13. 
Transcription 
6 exons; mRNA linear (NM_173842.2) with 1794 
bp. IL1RN mRNA does not contain the AUUUA 
sequence that has been implicated in shortening the 
half-life of several cytokine mRNAs (Carter et al., 
1990). 
Pseudogene 
No pseudogenes have been identified. 
Protein 
Note 
The IL1RN precursor protein consists of 177 amino 
acids and has a molecular weight of 20055 Daltons. 
The IL1RN cDNA encodes a 152 amino acid 
protein preceded by a 25 amino acid secretory 
leader sequence indicating that this protein takes a 
more straightforward pathway out of the cell than 
IL1.  
IL1RN is found extracellularly in its mature form 
without requiring extracellular cleavage to its 
mature form. The mature protein consists in ~159 
amino acids (Arend, 1991; Haskill et al., 1991). 
The IL1RN gene produces two forms of IL1RN: 
intracellular (icIL1RN) and secreted (sIL1RN) 
which are controlled by different promoter regions 
(Redlitz et al., 2004). 
Description 
The protein consists of 177 amino acids, and a 
molecular weight of 20KDa. The amino acid 
sequence homology is 26-30% to IL1β and 19% to 
IL1α. The mature protein is a single 
nonglycosylated polypeptide of 150 amino acids 
approximately, further, this protein contains a 25 
amino acids leader sequence (Eisenberg et al., 
1990). 
Expression 
Practically, IL1RN is expressed in whole organism, 
in both adult and embryonic stages. IL1RN is 
expressed physiologically in different tissues like 
lymph node, brain, heart, colon, adipocyte, kidney, 
liver, lung, thyroid, adrenal gland, skin, placenta, 
ovary, prostate and testis (GeneCards). 
Furthermore, IL1RN is present in numerous cancers 
such as gastric cancer (Iizuka et al., 1999), cervical 
cancer (Fujiwaki et al., 2003), lymphoblastic 
(Hulkkonen et al., 2000) and myelogenous (Estrov 
et al., 1992) leukemias, breast cancer (Miller et al., 
2000), endometrial cancer (Van Le et al., 1991), 
bladder cancer (Ahirwar et al., 2009), colorectal 
cancer (Viet et al., 2005), lung cancer (Lind et al., 
2005) and brain tumors (Oelmann et al., 1997; Ilyin 
et al., 1998). 
Localisation 
There are four isoforms of IL1RN. The IL1RN 
isoform 1 is secreted, and the other three, IL1RN2, 
IL1RN3 and IL1RN4 have localization into 
cytoplasm (Arend and Guthridge, 2000). 
 
 
Table of four IL1RN isoforms, showing the amino acid sequences and other protein characteristics. 
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When IL1 binds to IL1-receptor induces proinflammatory reaction and gene expression. Blocking of the receptor by IL1RN 
prevents this response. 
 
 
Function 
The protein binds to interleukin 1 receptor (IL1R1) 
and inhibits the binding of interleukin 1 alpha and 
beta (IL1A and IL1B) (Arend, 1991; Arend and 
Gabay, 2000), modulating the immune response 
(Dinarello, 2011).  
IL1RN competes with IL1 for binding two IL1 cell 
surface receptors type I and type II (IL1RtI and 
IL1RtII), however, when it occupies the receptor it 
does not trigger the cellular responses typical of IL1 
which includes the production of secondary 
substances that mediate inflammatory responses 
and tissue remodeling (Dinarello, 2011). 
Homology 
Homologs of IL1RN protein are highly conserved 
in different species (NCBI). 
Rattus norvegicus: Il1rn (178 amino acids). 
Mus musculus: Il1rn (159 aa). 
Equus caballus: IL1RN (177 aa). 
Bos taurus: IL1RN (174 aa). 
Canis lupus familiaris: IL1RN (176 aa). 
Tursiops truncatus: IL1RN (177 aa). 
Gallus gallus: IL1RN (163 aa). 
Macaca fascicularis: IL1RN (177 aa). 
 
Mutations 
Note 
Allelic variants 
Germinal 
The most common variation in the IL1RN gene is 
the penta allelic variable number of tandem repeat 
of 86 base pair located in intron 2 which results in a 
short allele with two repeats (IL1RN*2), and long 
alleles (IL1RN*L): allele 1 (four repeats), allele 3 
(five repeats), allele 4 (three repeats) and allele 5 
(six repeats).  
The most frequent allelic form is allele 1 followed 
by allele 2, the rest of the alleles are very rare.  
It has been reported that the allele 2 causes a 10-
fold increased seric IL1RN (Danis et al., 1995). 
Furthermore, Redlitz and cols, found that allele 1 
has a 4-fold increase of the production of icIL1RN 
compared to allele 1 (Redlitz et al., 2004). 
Two other germline mutations: Gln57Ter 
(rs121913162) and Glu80Ter (rs121913161) have 
been associated with the deficiency of IL1RN 
leaning to an autoinflammatory (Aksentijevich et 
al., 2009). 
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Somatic 
The somatic mutation rs148026279 producing the 
protein change Phe148Val has been associated with 
malignant melanoma (Wei et al., 2011). 
Implicated in 
Various cancers 
Note 
The IL1 cluster has been strongly associated with 
different types of cancer. Multiple studies have 
shown that IL1RN, included in this cluster is 
altered in cancer development. IL1RN plays a 
central role in the response to pathogens associated 
with cancer etiopathogenesis (Roberge et al., 1996; 
Hurme and Helminen, 1998; Wang et al., 2003; 
Queiroz et al., 2004; Rocha et al., 2005) and 
chronic inflammation, well described as an 
important risk factor in cancer development 
(Hanahan and Weinberg, 2011; Baniyash et al., 
2014; Khatami, 2014), thus, cytokines such as 
IL1RN could be used as risk and progression 
markers in the future.  
In the meta-analysis performed by Zhang and cols., 
which included 71 studies of multiple cancers, with 
14854 cases and 19337 controls, the research group 
found a consistent association with gastric cancer. 
IL1RN polymorphisms frequency is significantly 
different across ethnicities; the frequency of allele 2 
is significantly lower in Asian controls (11.14%) 
compared to Caucasian controls (26%) (Zhang et 
al., 2011). 
Gastric cancer 
Note 
Gastric cancer after H. pylori infection 
susceptibility has been linked with IL1RN gene. 
Studies of genetic association have shown an 
increased risk of gastric cancer with the allele 
IL1RN*2 across different populations (El-Omar et 
al., 2000; Furuta et al., 2002; Alpizar-Alpizar et al., 
2005; Garza-Gonzalez et al., 2005; Palli et al., 
2005; Morgan et al., 2006; Oliveira et al., 2012). 
However, IL1RN*2 has been also been associated 
independently of H. pylori infection (Mattar et al., 
2013). 
Oncogenesis 
The inflammatory response after H. pylori infection 
has been linked to the IL1 gene cluster. The 
infection induces the synthesis of IL1B which binds 
to its target receptor and starts the inflammatory 
response against the pathogen (Sierra et al., 2008). 
The IL1RN competitively binds to the IL1 receptor 
with the same affinity as IL1 without activating the 
inflammation cascade, modulating the effects of 
IL1B. The severity of damage caused by 
inflammatory response in mucosal tissue is 
regulated by the balance between these cytokines. 
The short allele IL1RN*2, is associated with 
increased levels of IL1B, which could probably 
have a significant effect on increased inflammatory 
damage (Santtila et al., 1998). 
It has also been described that IL1B inhibits gastric 
secretion (Sugimoto et al., 2009), and it is 100 
times more potent than proton pump inhibitor 
(Wolfe and Nompleggi, 1992), which favors the 
corpus colonization, causing atrophic gastritis that 
may evolve to gastric carcinoma. El-Omar and 
cols., demonstrated an increased risk of 
hypochlorhydria when IL1RN*2 allele is present in 
homozygous form (El-Omar et al., 2000). 
Cervical cancer 
Oncogenesis 
Cervical cancer is associated with the infection by 
human papillomavirus (HPV), however, although 
millions of women are infected with high-risk HPV 
subtypes, only a subset of them develop cervical 
cancer, reveling an important role of host immunity 
in cervical carcinogenesis. Various studies have 
observed a significant contribution of IL1RN*2 
allele to increase risk of cervical cancer (Sehouli et 
al., 2002; Mustea et al., 2003; Tamandani et al., 
2008; Sousa et al., 2012). Moreover, Sousa and 
cols, found that IL1RN*2 correlated not only with 
cervical cancer but with cervical lesions and earlier 
onset of cases with cervical lesion and cancer in 
patients homozygous IL1RN*2 (Sousa et al., 2012). 
Tamandani and cols, showed a protective 
association of heterozygous IL1RN*1*2 and 
homozygous IL1RN*2 and HPV 16 and 18 
subtypes but a risk association with 
adenocarcinoma (Tamandani et al., 2008). 
Breast cancer 
Prognosis 
In Caucasian women it has been described that 
IL1RN*2 is associated with shortened disease free 
survival and overall survival (Grimm et al., 2009). 
In this study, Grimm and cols reported that only 
80% of women positive to IL1RN*2 survived after 
12 months, and 30% had died after 48 months; the 
disease-free survival was only of 40% in women 
with IL1RN*2 compared with 80% in women with 
the wild allele (Grimm et al., 2009). In respect to 
the long alleles of IL1RN gene, allele *2 has been 
reported to be modify the binding on the IL1 
receptor, leading to less efficient inhibition of IL1a 
and IL1b (Tarlow et al., 1993), this might result in a 
proinflammatory status and enhanced tumor 
aggressiveness, which is likely to result in a 
shortened survival of women with breast cancer 
(Grimm et al., 2009). 
Oncogenesis 
Breast cancer oncogenesis has been associated with 
polymorphisms in different cytokines (Gomez-
Flores-Ramos et al., 2013; Dinarello, 2006) and it 
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has been widely discuss the participation of chronic 
inflammation in breast carcinogenesis (Honma et 
al., 2002). Different research groups have studied 
the association of IL1RN and breast cancer risk. 
Lee and cols, found a decreased breast cancer risk 
with the short allele (*2) and a higher risk of cancer 
in women with the long allele and higher body 
mass index (Lee et al., 2006). Zhang and cols, 
performed a meta-analysis study and found a 
similar trend with allele IL1RN*2 (Zhang et al., 
2011), however, with this apparent diminish in risk 
for breast cancer, other studies have found an 
elevated risk of earlier recurrence of breast cancer 
in women with IL1RN*2 allele (Grimm et al., 
2009). 
Bladder cancer 
Oncogenesis 
Significant association with higher risk of bladder 
cancer has been described to Il1RN*2 allele (Bid et 
al., 2006; Ahirwar et al., 2009). This allele has been 
proposed as a potential marker for genetic 
susceptibility to bladder cancer (Ahirwar et al., 
2009). Studies have showed that IL1RN*2 
increases the production of IL1B significantly 
(Santtila et al., 1998; Nazarenko et al., 2008) and it 
can induce angiogenesis via upregulation of COX-2 
or inducible nitric oxide and vascular endothelial 
growth factor which may contribute to tumor 
growth (Rahman et al., 2001). 
Colorectal cancer 
Prognosis 
IL1B and IL1RN have been shown to play an 
important role in angiogenesis of early onset 
tumors, Viet and cols, found that allele *1 was 
more frequent in patients with localized disease 
compared with disseminated disease, being allele 
*2 associated with dissemination of the disease 
(Viet et al., 2005). The study of Lurje and cols, 
showed that patients with IL1RN VNTR had a 
significant six-fold increment in relative risk of 
developing tumor recurrence compared to those 
patients with the wild allele. The IL1RN 
homozygous *2/*2 genotype had a median time-to-
recurrence of 5.7 years, compared with 10.7 years 
for those with *1/*1 genotype (Lurje et al., 2009).  
Serum levels of IL1Ra have been studies as 
prognostic factors as well, in colorectal cancer 
patients, low preoperative IL1Ra was associated 
with postoperative infection (Miki et al., 2005). 
Oncogenesis 
Colorectal cancer has been widely associated in 
epidemiological and experimental studies with 
chronic inflammation. Viet and cols, found that the 
allele IL1RN*3 of VNTR variant was significantly 
increased in patients compared with controls, and 
the allelic distribution of this VNTR differed 
between colon and rectum, being allele *3 more 
abundant in colon (Viet et al., 2005). Other 
polymorphic sites have been associated with 
colorectal oncogenesis. Burada and cols, linked the 
polymorphism IL1RN +2018C>T with colorectal 
cancer, allele C was found to be enriched in patients 
with cancer compared to controls. This study 
described that this association was limited to early 
stage I and II (Burada et al., 2013).  
In attempt to find markers for colorectal cancer 
disease, serum cytokines levels have been studied; 
Iwagaki and cols, found that patients with 
colorectal cancer present reduced level of IL1Ra 
relative to normal controls, indicating that cancer 
patients have an immunologic disorder (Iwagaki et 
al., 1997). 
Lung cancer 
Oncogenesis 
Tobacco smoking is the main risk factor for lung 
cancer, however, only 10-15% of smokers develop 
lung cancer, suggesting that genetic factors are 
important in individual susceptibility for this 
disease (Ridge et al., 2013). Lind and cols, found 
that individuals homozygous for IL1RN*1 in 
combination with the allele IL1B-31T had an 
increased risk of non-small cell lung cancer and a 
two-fold higher level of bulky/hydrophobic DNA 
adducts in the long in patients with IL1RN*1 (Lind 
et al., 2005). These data were confirmed in Chinese 
patients, with a decreased risk of 32% in patients 
with IL1RN*2 allele (Hu et al., 2006). On the other 
hand, Lim and cols, found a 5-fold-time increased 
risk in lung cancer in never-smokers patients with 
the IL1RN*2 (Lim et al., 2011), but these results 
are not consistent, since Hu and cols, found a 
reduced risk in non-smokers with squamous cell 
carcinoma (Hu et al., 2006). 
Brain cancer 
Oncogenesis 
Inflammatory status of brain tumors has been 
studied, and it has been shown that IL1 cluster is 
important in development and progression of 
neoplasia. Ilyin and cols, investigated the levels of 
IL1 and IL1Ra in pediatric astrocytomas, 
ependymomas and primitive neuroectodermal 
tumors. The results demonstrated a significant 
different profile among tumors. Pilocytic, 
nonpilocytic and anaplastic astrocytomas had a 
significant increase of mRNA of IL1 beta and its 
receptor, but low levels of IL1Ra mRNA, 
suggesting an imbalance between stimulatory and 
inhibitory cytokines in brain tumors growth and 
development via autocrine/paracrine mechanisms 
(Ilyin et al., 1998). 
Oelmann and cols, performed a study in cell lines 
of glioblastoma showed that IL1Ra modulates 
glioblastoma growth. Experimental addition of 
neutralizing antibody against IL1Ra down-
IL1RN (interleukin 1 receptor antagonist) Gómez-Flores-Ramos L, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(10) 751 
regulated growth of IL1 and IL1Ra producing 
glioblastoma, the authors suggest that an autocrine 
production of IL1Ra can counteract IL1 function 
and represent a basic escape mechanism malignant 
growth in some glioblastomas (Oelmann et al., 
1997). 
Septic shock in pediatric population 
with acute lymphoblastic leukemia 
Prognosis 
The presence of IL1RN*2 allele was associated 
with significant susceptibility to septic shock in 
pediatric patients with acute lymphoblastic 
leukemia by (Zapata-Tarres et al., 2013). The 
patients studied by Zapata-Tarres and cols, were 
susceptible to septic shock.  
The association between sepsis and IL1RN*2 has 
been reported previously, Fang and cols, reported 
an increased relative risk of sepsis in patients 
homozygous IL1RN*2 as well heterozygous 
patients (Fang et al., 1999). Arnalich and cols 
reported a significant increase in the risk of death 
after severe sepsis in patients with IL1RN*2 and 
that the allele is associated with decreased 
production of IL1Ra in culture but higher 
concentrations of the protein in serum (Arnalich et 
al., 2002). 
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